All therapeutic modalities including the below will be considered
- small molecules
- nucleic acids
- antibodies, peptides
- antisense oligonucleotides (ASOs)
- gene therapies
- cell therapies
Preferred early-stage target opportunities demonstrating strong disease rationale and application in preliminary in vitro validation.
LAB eN² can help optimize your drug candidates to demonstrate in vivo proof of concept and develop safety and absorption, distribution, metabolism and excretion (ADME) data packages.
Learn more about how to apply here